Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers

NCT01312909 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01312909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01312909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2011
Completion date
January 31, 2018
Enrollment
312 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation